David Novak

Item: David Novak
Rating: 0.58
Author: StockAnalysis.com

Stock Analyst at Raymond James

(0.58)

# 4,140

Out of 5,141 analysts

Total ratings

42.86%

Success rate

-13.85%

Average return

Main Sectors:

Top Industries:

Stocks Rated by David Novak

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	ZYME Zymeworks	Downgrades: Outperform	$74	$22.72	+225.70%	6	Dec 10, 2021
	CBIO Crescent Biopharma	Maintains: Outperform	$300 → $270	$11.60	+2,227.59%	1	Feb 4, 2021

Zymeworks

Dec 10, 2021

Downgrades: Outperform

Price Target: $74

Current: $22.72

Upside: +225.70%

Crescent Biopharma

Feb 4, 2021

Maintains: Outperform

Price Target: $300 → $270

Current: $11.60

Upside: +2,227.59%